Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNS-3545 in Healthy Adult Subjects
NCT07225296Phase 1Completed
- Sponsor
- Genosco
- Start
- Nov 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing GNS-3545 with GNS-3545 Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Nov 2025; status: completed.
02
Drugs
GNS-3545
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07225296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07225296.